Accelerated ageing of body organs from blood proteins
Is it possible to measure the “biological age” of each of your organs from a small sample of blood? Get the low down here, by scientific co-founder Prof Michael Valenzuela
MedNous June 2023
Invited commentary by co-founder Michael Valenzuela in June 2023 edition of MedNous biotech trade publication.
Lecanemab doesn’t appear to work in women
Everyone’s talking about lecanemab but missed a critical point — it doesn’t seem to work in women.
Guest lecture: State of the Art of Cell Therapy for Neurodegenerative Disorders
Wednesday Nov 23 in Sydney! Cell therapy pioneer Dr Jeffrey Schweitzer of MGH/Harvard to give special presentation.
New Alzheimer’s treatment on horizon as dementia reversed for first time in dogs
S2N has achieved what no one else has to date – reversal of a dementia-like syndrome in a natural animal form of Alzheimer’s disease.
End of the road for amyloid
Adverse FDA Adcomm judgement of Biogen’s aducanumab signals end of road for amyloid.
World first IPS cell therapy for Parkinson’s disease
Chief Scientist Prof Michael Valenzuela runs through the basics of this pioneering n=1 proof of concept trial.
Alzheimer Biomarkers
What exactly are biomarkers and what’s the state of play in Alzheimer’s disease? S2N chief scientist Prof Michael Valenzuela explains.
The amyloid cul de sac
For researchers searching for an Alzheimer dementia cure, a recent large negative clinical trial based directly on the amyloid hypothesis underscores the idea’s growing irrelevance that may even be holding progress back.